Transfer of Umicore’s Platinum Active Pharmaceutical Ingredient business outside of South America to Heraeus

Umicore announces the sale of its Platinum Active Pharmaceutical Ingredient (API) business outside of South America to Heraeus Precious Metals, the precious metals division of the Heraeus Group, with immediate effect. 

The sale does not include Umicore’s Platinum API business and production facility in South America, or the non-Platinum molecules that Umicore will continue to supply globally.

“Heraeus Precious Metals is the ideal partner for our customers in the Platinum API business outside of South America as they share our commitment to excellent quality in a transaction that provides synergies for all parties.”

Michael Schwarz, Commercial Director Global API Business at Umicore

“Our mission is to reliably provide customers with the highest quality products – ensuring effective treatment for as many cancer patients as possible,” said Dr. Andrea Lamberti, Head of Pharmaceutical Ingredients at Heraeus Precious Metals. “In this light, this is a very exciting business opportunity for us. The combination of the businesses brings synergies that enable us to offer a strong portfolio at competitive prices – without compromises on quality.”